Uso isolado ou combinado de etidronato, risedronato, pravastatina e ipriflavona no tratamento da osteoporose induzida por ovariectomia em ratas

• Autor(a) principal: Amaral, Gláucia Guimarães
• Data de Publicação: 2010
• Tipo de documento: Dissertação
• Idioma: por
• Título da fonte: LOCUS Repositório Institucional da UFV
• Texto Completo: http://locus.ufv.br/handle/123456789/5046
• topic: Osteoporose; Dexametasona; Bisfofonato; Osteoporosis; Dexamethasone; Bisphosphonates; CNPQ::CIENCIAS AGRARIAS::MEDICINA VETERINARIA::CLINICA E CIRURGIA ANIMAL::FARMACOLOGIA E TERAPEUTICA ANIMAL

This work was in an assay to study the possible treatment of osteoporosis induced by ovariectomy through the use of isolated and combined, using, in this case, half the doses of the compounds isolated etidronate, risedronate, pravastatin, and ipriflavone, which are agents that have shown positive effects on bone metabolism. Wistar rats, adult, weighing on average 250g were used. The process of induction of osteoporosis was made by surgery when the animals were 5 months old, for retroumbilical incision, giving access to the abdominal cavity under general anesthesia using the combination of ketamine and xylazine at doses of 50 and 5 mg / Kg , respectively, except for animals that constituted the control group (G1). After 12 weeks, was started to drug treatment. The animals were randomly divided into 11 experimental groups, with groups consisting of 6 animals. Group 1 (G1), control, consisted of animals that did not undergo surgery or treatment. In group 2 (G2) there was only surgery. The other groups, besides the surgical process, were treated with medication, group 3 (G3) received etidronate (6 mg / kg), group 4 (G4) risedronate (0.07 mg / kg), group 5 ( G5) pravastatin (0.6 mg / kg), group 6 (G6) ipriflavone (100 mg / kg), group 7 (G7) etidronate and pravastatin (3 mg / kg and 0.3 mg / kg), Group 8 (G8) etidronate and ipriflavone (3 mg / kg and 50 mg / kg), Group 9 (G9) risedronate and pravastatin (0.035 mg / kg and 0.3 mg / kg), group 10 (G10) risedronate and ipriflavone (0.035 mg / kg and 50 mg / kg) and Group 11 (G11) pravastatin and ipriflavone (0.3 mg / kg and 50 mg / kg). All substances were administered orally daily for 30 days. Immediately before the animals were euthanized at 35 days after treatment, blood was collected for serum calcium, phosphorus, albumin and total protein analyzed in the equipment Alizé multiparametric biochemistry and bone alkaline phosphatase analysis equipment Access Immunoassay System chemiluminescence of Beckman Coulter. Then, by the dissection of muscle tissue, the right tibias were collected and frozen for densitometric study using bone densitometry X-ray with Smart Scan DPX-ALPHA, with special software for small animals and the left tibias were collected after of fixed, decalcified and were routinely processed for histomorphometric study, the sections were stained with hematoxylin and eosin for evaluation of trabecular bone density was applied to the calculation method for planimetric point count. The assay was performed according to a randomized design with 11 treatments in six replicates. The results were subjected to analysis of variance. The control groups (G1 and G2) were compared using the F test (p <0.05). Treated groups (G3 to G11) were compared by the Tukey multiple comparison test, the 5% probability. Comparisons were also performed between treated groups and controls G1 and G2, applying Dunnett test at 5% probability. The results showed no significant between the control group (G1) and the osteoporotic group (G2), as well as between the treated groups (G3 to G11) for values of serum calcium, phosphorus, albumin, total protein and bone alkaline phosphatase. By densitometry, and histomorphometry was possible to observe the induction of osteoporosis by ovariectomy. Treated groups compared to the osteoporotic group G2, all treatments showed statistically significant differences, for density and histomorphometry. Thus, the drug etidronate, risedronate, pravastatin, and ipriflavone, used isolated or in combination, showed positive effects on bone metabolism and effective in restoring bone tissue in experimental conditions. Whereas the association of drugs constituted half of the doses used in isolation, the possibility of reduced side effects with the combination becomes a promising alternative for the treatment of osteoporosis.